Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free JMAC Stock Alerts

Maxpro Capital Acquisition (JMAC) Competitors

Maxpro Capital Acquisition logo
$14.08 -0.22 (-1.56%)
As of 05/22/2026
Compare

JMAC vs. EIKN, AVTE, ZVRA, GYRE, and ACRS

Should you buy Maxpro Capital Acquisition stock or one of its competitors? MarketBeat compares Maxpro Capital Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maxpro Capital Acquisition include EIKN (EIKN), Aerovate Therapeutics (AVTE), Zevra Therapeutics (ZVRA), Gyre Therapeutics (GYRE), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Maxpro Capital Acquisition compare to EIKN?

Maxpro Capital Acquisition (NASDAQ:JMAC) and EIKN (NASDAQ:EIKN) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
Maxpro Capital AcquisitionN/A N/A N/A
EIKN N/A N/A N/A

EIKN has a consensus price target of $25.20, suggesting a potential upside of 130.98%. Given EIKN's stronger consensus rating and higher probable upside, analysts clearly believe EIKN is more favorable than Maxpro Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EIKN
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, EIKN had 4 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 4 mentions for EIKN and 0 mentions for Maxpro Capital Acquisition. EIKN's average media sentiment score of 0.99 beat Maxpro Capital Acquisition's score of 0.00 indicating that EIKN is being referred to more favorably in the news media.

Company Overall Sentiment
Maxpro Capital Acquisition Neutral
EIKN Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A
EIKNN/AN/AN/AN/AN/A

Summary

EIKN beats Maxpro Capital Acquisition on 5 of the 7 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Aerovate Therapeutics?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Maxpro Capital Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maxpro Capital AcquisitionN/A N/A N/A
Aerovate Therapeutics N/A -90.19%-77.47%

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company Overall Sentiment
Maxpro Capital Acquisition Neutral
Aerovate Therapeutics Neutral

Summary

Maxpro Capital Acquisition beats Aerovate Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Zevra Therapeutics?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Zevra Therapeutics has a net margin of 101.58% compared to Maxpro Capital Acquisition's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Maxpro Capital Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Maxpro Capital AcquisitionN/A N/A N/A
Zevra Therapeutics 101.58%51.49%28.86%

Zevra Therapeutics has higher revenue and earnings than Maxpro Capital Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A
Zevra Therapeutics$106.47M5.57$83.23M$1.995.04

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has a consensus price target of $23.33, indicating a potential upside of 132.64%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Maxpro Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zevra Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Zevra Therapeutics'average media sentiment score.

Company Overall Sentiment
Maxpro Capital Acquisition Neutral
Zevra Therapeutics Neutral

Summary

Zevra Therapeutics beats Maxpro Capital Acquisition on 8 of the 10 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Gyre Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 180.53%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gyre Therapeutics is more favorable than Maxpro Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Gyre Therapeutics had 6 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 6 mentions for Gyre Therapeutics and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 beat Gyre Therapeutics' score of -0.39 indicating that Maxpro Capital Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Gyre Therapeutics Neutral
Maxpro Capital Acquisition Neutral

Gyre Therapeutics has higher revenue and earnings than Maxpro Capital Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$116.59M5.04$5.03M-$0.09N/A
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Maxpro Capital Acquisition has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Maxpro Capital Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics-5.44% 3.13% 2.67%
Maxpro Capital Acquisition N/A N/A N/A

Summary

Gyre Therapeutics beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Maxpro Capital Acquisition has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Maxpro Capital Acquisition's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aclaris Therapeutics-832.58% -55.89% -38.49%
Maxpro Capital Acquisition N/A N/A N/A

Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maxpro Capital Acquisition has lower revenue, but higher earnings than Aclaris Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$7.83M80.62-$64.92M-$0.56N/A
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A

In the previous week, Aclaris Therapeutics' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score.

Company Overall Sentiment
Aclaris Therapeutics Neutral
Maxpro Capital Acquisition Neutral

Aclaris Therapeutics presently has a consensus price target of $11.29, indicating a potential upside of 149.68%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Maxpro Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aclaris Therapeutics beats Maxpro Capital Acquisition on 7 of the 11 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JMAC vs. The Competition

Export
MetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ Exchange
Market Cap$189.13M$248.95M$4.26B$12.34B
Dividend YieldN/A3.22%5.93%5.28%
P/E RatioN/A2.2721.9025.66
Price / SalesN/A0.14180.6186.31
Price / CashN/A123.3055.6856.67
Price / BookN/A25.6634.857.14
Net IncomeN/A-$8.98M$112.32M$335.98M
7 Day Performance-6.10%-0.03%3.55%4.15%
1 Month Performance6.04%0.66%3.59%2.54%
1 Year Performance98.94%0.99%15.80%35.06%

Maxpro Capital Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JMAC
Maxpro Capital Acquisition
N/A$14.09
-1.6%		N/A+98.9%$189.13MN/AN/A2,021
EIKN
EIKN
N/A$13.25
+0.5%		$25.20
+90.2%		N/A$713.55MN/AN/A384
AVTE
Aerovate Therapeutics
N/A$24.13
-3.7%		N/A+215.9%$699.41MN/AN/A20
ZVRA
Zevra Therapeutics
3.5146 of 5 stars		$11.01
-5.6%		$23.33
+111.9%		+16.0%$689.28M$106.47M5.5320
GYRE
Gyre Therapeutics
2.1989 of 5 stars		$6.55
-6.4%		$17.00
+159.5%		-30.2%$679.20M$116.59MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JMAC) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel